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Electrochemical Biosensing in Cancer Diagnostics and
Follow-up
Maria Freitas,[a] Henri P. A. Nouws,*[a] and Cristina Delerue-Matos[a]
Abstract: In cancer, screening and early detection are
critical for the success of the patient’s treatment and to
increase the survival rate. The development of analytical
tools for non-invasive detection, through the analysis of
cancer biomarkers, is imperative for disease diagnosis,
treatment and follow-up. Tumour biomarkers refer to
substances or processes that, in clinical settings, are
indicative of the presence of cancer in the body. These
biomarkers can be detected using biosensors, that,
because of their fast, accurate and point of care applic-
ability, are prominent alternatives to the traditional
methods. Moreover, the constant innovations in the
biosensing field improve the determination of normal and/
or elevated levels of tumour biomarkers in patients’
biological fluids (such as serum, plasma, whole blood,
urine, etc.). Although several biomarkers (DNA, RNA,
proteins, cells) are known, the detection of proteins and
circulating tumour cells (CTCs) are the most commonly
reported due to their approval as tumour biomarkers by
the specialized entities and commonly accepted for
diagnosis by medical and clinical teams. Therefore,
electrochemical immunosensors and cytosensors are vastly
described in this review, because of their fast, simple and
accurate detection, the low sample volumes required, and
the excellent limits of detection obtained. The biosensing
strategies reported for the six most commonly diagnosed
cancers (lung, breast, colorectal, prostate, liver and
stomach) are summarized and the distinct phases of the
sensors’ constructions (surface modification, antibody
immobilization, immunochemical interactions, detection
approach) and applications are discussed.
Keywords: cancer biomarker · electrochemical biosensing · immunosensor · cytosensor · nanomaterial
1 Introduction
The International Agency for Research on Cancer
(IARC) estimated that in 2012 there were 14.1 million
new cancer cases, 8.2 million cancer deaths and 32.6 mil-
lion people living with cancer (within 5 years of diagnosis)
worldwide [1].
According to the World Health Organization (WHO)
cancer is a generic term for a large group of diseases that
can affect any part of the body. The major feature of
cancer is the rapid creation of abnormal cells that grow
beyond their usual boundaries, and can then spread to
other organs, a process referred to as metastasis, which is
the major cause of death from cancer [2].
The most commonly diagnosed cancers in 2012 were
lung (1.82 million), breast (1.67 million), colorectal
(1.36 million), prostate (1.1 million cases), stomach
(951000 cases) and liver (782000 cases). These six cancers
represent 55 percent of the global incidence burden in
2012 [1].
When cancer is present in the body the levels of
several substances can be altered both in or on tumour
cells as well as in biological fluids (blood, urine, etc.).
These substances are produced by cancer cells or by other
cells of the body in response to cancer or certain benign
(noncancerous) conditions [3] and are referred to as
biomarkers. This includes abnormalities in DNA (germ-
line or somatic), RNA, proteins, metabolites, and abnor-
mal cellular or tissue processes. A particular cancer type
can be detected through qualitative and/or quantitative
analysis of a certain biomarker [4]. These biomarkers may
also be used to monitor the response to treatment and
allow patient follow-up. The identification of circulating
(peripheral blood) biomarkers, analysed in so called
“liquid biopsies”, would have enormous implications in
diagnosis and treatment [5] and avoid the traditional
invasive biopsy.
2 Cancer Biomarkers
Currently, a wide range of specific biomolecules has been
proposed as potential biomarkers for cancer detection.
However, the vast majority still need to be validated for
use in the clinical setting, mainly because of lack of
specificity and/or sensitivity. Protein biomarkers can be
detected in distinct cancer stages and are classified as
prognostic, therapeutic or diagnostic biomarkers. The
screening and evaluation of an individual‘s susceptibility
to cancer can contribute and support the decisions of
medical teams, underlying the risk of incidence or
progression. The detection is normally conducted in bio-
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logical fluids, with serum being the most desirable testing
matrix in clinical tests. This non-invasive practise has
revitalized early detection [6].
The electrochemical analysis of circulating protein
biomarkers is the main focus of this review because of
their potential prognostic value. However, a detailed
description of these biomarkers is beyond the scope of
this review and the authors’ expertise. Therefore, a short
summary of the common protein biomarkers used for the
development of electrochemical immunosensors related
to the six most commonly diagnosed cancers in 2012 is
presented in Table 1.
(i) Lung cancer, the most incident cancer-type with the
highest cancer mortality rate worldwide, is mainly divided
into two broad categories: small-cell lung carcinoma
(SCLC) and non-small cell lung carcinoma (NSCLC).
Neuron specific enolase (NSE) is a specific protein
marker in lung cancer detection and a high percentage of
patients with SCLC have elevated serum NSE concen-
trations at diagnosis. On the other hand, cytokeratin
fragment 21-1 (CYFRA 21-1), squamous cell carcinoma
antigen (SCC) and carcinoembryonic antigen (CEA) have
been associated with NSCLC cases, which represent the
vast majority of lung cancer cases [7]; (ii) Breast cancer is
a healthcare concern of women worldwide. The protein
biomarkers with evidence of clinical utility for breast
cancer include CEA, Human epidermal growth factor
receptor 2 (HER2) and Cancer Antigen 15-3 (CA 15-3)
[8]; (iii) Colorectal cancer (CRC) is the second most
commonly diagnosed cancer among women and third
among men worldwide. Two of the most widely known
serum protein biomarkers for CRC are the Cancer
Antigen 19-9 (CA 19-9) and CEA. Simultaneous detec-
tion of both biomarkers is beneficial in evaluating the
therapeutic effect [9]; (iv) Prostate cancer is the most
common cancer-type in men. Prostate specific antigen
(PSA) is the classic and the most widely used protein
biomarker for clinical diagnosis [10]; (v) Hepatocellular
carcinoma (HCC) is the fifth most common cancer,
representing more than 90% of primary liver cancer, and
is frequently detected by a-fetoprotein (AFP). Never-
theless, three serum biomarkers are normally suggested to
determine the risk of liver cancer: AFP, AFP-L3, and des-
gamma-carboxy-prothrombin (DCP) [11]; (vi) Stomach
cancer, also known as gastric cancer, remains one of the
leading challenges in oncologic research because of its
frequent occurrence and poor prognosis. Besides the
Table 1. Some protein cancer biomarkers.
Cancer Protein Biomarker Ref
Lung Neuron-Specific Enolase
(NSE)
Squamous Cell Carcinoma
antigen (SCC)
[14–19]
[20–22]
Breast Human epidermal
growth factor
receptor 2 (HER2)
Cancer Antigen 15-3
(CA 15-3)
[23–30]
[31–39]
Colorectal and
Stomach
Cancer Antigen 19-9
(CA 19-9)
[40–43]
Prostate Prostate-Specific Antigen
(PSA)
[44–69]
Liver a-1-Fetoprotein (AFP) [70–99]
Stomach Cancer Antigen 72-4
(CA 72-4)
Interleukin-6 (IL-6)
[100–101]
[102]
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classical serum-based protein biomarkers associated with
stomach cancer (CEA, CA 19-9 and Cancer Antigen 72-4
(CA 72-4)), the interleukin IL6 is also considered a
valuable biomarker for this type of cancer [12].
As referred previously, several classic biomarkers are
eligible for cancer diagnosis. However, a careful and
judicious decision is often necessary to avoid false results
and thus a misdiagnosis. The simultaneous (multiplexed)
detection of distinct biomarkers could avoid these prob-
lems. For example, CEA leads to effective cancer
detection, but is non-specific (it is commonly used to
monitor several cancer types, such as colorectal, lung,
gastric, pancreas, liver and breast) So, its overexpression
only indicates the presence of an elevated amount of
cancer cells [13]. Therefore, the combination of CEA and
other more specific biomarkers can greatly contribute to a
more reliable diagnosis.
Throughout this review the state of the art of electro-
chemical immunosensors and immunoassays in the field of
cancer analysis is discussed. Besides this, because of the
large number of recent developments related to circulat-
ing tumor cells (CTCs), the detection of these cells using
electrochemical devices is also included. For the selected
analytical strategies included in this work the actual
design, construction and detection approach are analysed
and discussed. The most relevant topics related to the
recently published electrochemical sensors are presented
in summarized tables.
3 Electrochemical Biosensors
The established tests to determine cancer biomarkers are
based on invasive methods, such as biopsies, followed by
immunohistochemistry (IHC) and fluorescent in situ hy-
bridization (FISH) analysis methods [103]. Although the
detection of protein cancer biomarkers in blood or serum
is not a routine practice, their analysis is possible and is
mainly based on enzyme-linked immunosorbent assays
(ELISA). However, some of these assays are not
sufficiently sensitive for the detection of low biomarker
concentrations [104] and in the prognostic detection,
which is then susceptible to produce false results [105].
To overcome this problem major efforts have been
made to develop more sensitive analytical techniques for
biomarker detection, with a special emphasis on biosen-
sors. The International Union of Pure and Applied
Chemistry (IUPAC) defines a biosensor as “an integrated
receptor-transducer device, which is capable of providing
selective quantitative or semi-quantitative analytical in-
formation using a biological recognition element” [106].
The biological recognition element can be DNA, an
antibody, an antigen, an enzyme, a whole cell, a cell
organelle, etc. The transducer is used to covert the
recognition event into an analytically useful signal. This
signal transduction can be based on electrochemical,
optical, piezoelectric and calorimetric principles. Biosen-
sors are usually designed to provide highly selective and
sensitive detection of target analytes through the use of
specific biological recognition elements combined with
highly sensitive detection techniques. Among the several
types of biosensors, the ones that employ electrochemical
detection (voltammetry, amperometry, potentiometry,
conductometry and electrochemical impedance spectro-
scopy) are the most widely studied. Electrochemical
biosensors are outstanding candidates for inclusion in
portable (point-of-care) systems because, besides their
fast responses, simplicity and ease of use, the instrumenta-
tion needed to perform the analysis has been reduced to
(low-cost) pocket-size dimensions. Furthermore, after the
development of individual assays for the biomarkers, their
combination to form multiplexed detection systems is
possible. Therefore, they can provide fast recording of
biomarker tumour profiles, which can play an important
role in early diagnosis and personalized medicine.
4 Electrochemical Immunosensors for Protein
Cancer Biomarker Analysis
Most of the electrochemical biosensors developed to date
for the detection of cancer protein biomarkers are
voltammetric or amperometric immunosensors. Therefore,
only these types of sensors are included in this review.
Furthermore, because of the large amount of published
studies and the extension of this review, only a reduced
number of these articles can be presented. The studies
included were retrieved from the Clarivate Analytics Web
of Science database (timespan: 2007–2017) by combining
the following keywords: cancer, protein biomarker, bio-
sensor and electrochemistry. Although studies without the
application in real samples were excluded, a few studies in
which these samples were not used were included because
of the interest of the construction of the sensing phase or
the detection label.
A summary of electrochemical immunosensors (EI)
for the analysis of protein biomarkers of lung (Table 2),
breast (Table 3), colorectal and stomach (Table 4), pros-
tate (Table 5), liver (Table 6) and stomach (Table 7),
cancer is presented. This summary focuses on several
important features of the sensors: the transducer electrode
and its surface modification, the immobilization strategy
of the capture antibody, the assay type, the electro-
chemical detection technique, the species detected, the
sample, and the limit of detection (LOD).
Promising new strategies have been implemented in
the design and construction of immunosensors for early
screening and cancer diagnosis. Voltammetric and am-
perometric sensors are especially interesting because of
the high sensitivity that can be attained. Electrochemical
biomarker detection has been carried out with distinct
techniques (amperometry, cyclic voltammetry (CV), linear
sweep voltammetry (LSV), differential pulse voltammetry
(DPV), square wave voltammetry (SWV), stripping
voltammetry and electrochemical impedance spectroscopy
(EIS)). Amperometry, CV and DPV are the most
commonly employed techniques because they provide low
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limits of detection (LOD), in the order of pg/mL and/or
fg/mL, for the cancer biomarkers reported in this review.
Voltammetric and amperometric sensors generally
incorporate a three-electrode configuration, composed of
working-, reference- and auxiliary electrodes, which are
placed in contact with the sample. Then the potential of
the working electrode (WE) is either varied within a
predefined potential range (voltammetry) or fixed at a
constant potential (amperometry) and the resulting cur-
rent is measured. The analytical process thus occurs at the
WE and therefore the recognition element is immobilized
on the surface of this electrode. The WE is a small-size
electrode or a screen-printed electrode (SPE) made of, for
example, carbon, gold, or platinum. Other specific work-
ing electrodes such as indium tin oxide (ITO) or paper
electrodes [33,53] are also employed depending on the
specifications or characteristics of the electrochemical
technique and the biosensor performance. Moreover, the
WE can be modified with nanostructures and distinct
materials such as carbon nanotubes, gold nanoparticles,
nanoelectrode ensembles (NEEs) prepared in track-
etched polycarbonate membranes [30], a multiwalled
carbon nanotube-ionic liquid (MW-CILE) [24], and a
three-dimensional Au nanowire array (3D AuNW) with
electropolymerized polypyrrole [55].
5 Electrode Surface Modification
Sensor surfaces modified with nanostructures can provide
an additional increment in the biosensor’s performance
and advanced development of portable devices that can
support early cancer diagnosis [107]. The WE’s surface is
therefore frequently modified with (nano) materials such
as metal (especially gold) nanoparticles or nanocompo-
sites and carbon nanostructures to (i) improve the
immobilization and the stability of the biological recog-
nition element, (ii) increase the recognition element’s
load, (iii) enhance the sensor’s sensitivity and/or (iv)
change the detection potential to minimize interferences
of other species. For the last two purposes, a redox
mediator can also be included in the surface modification
strategy.
Gold nanoparticles (AuNP) are an excellent nano-
material with favourable biocompatibility, good conduc-
tivity, and a high surface-to-volume ratio. As examples of
sensors using AuNPs, Ravalli et al. [25] developed a
sensitive biosensor based on easy immobilization of the
bioreceptor on AuNPs, electrodeposited on screen-printed
graphite. Marques et al. [27] used screen-printed carbon
electrodes, modified with AuNPs, for effective antibody
immobilization. In this work, the formation of the AuNPs
was achieved through electrodeposition of ionic gold by
applying a constant current followed by applying a
constant potential. Chu et al. [48] used AuNPs as a
substrate material to immobilize the antibodies and to
accelerate electron transfer. The AuNPs were prepared in
accordance with the conventional citrate method that
consists of reducing the gold nanoparticles with aTa
bl
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negatively charged ligand. Briefly, the synthesis involves a
solution containing HAuCl4 and ultrapure water that is
refluxed at high temperature. Then, under magnetic
stirring, the reducing agent sodium citrate is added. After
adequate cooling of the solution, a drop of the obtained
AuNPs was placed on the working electrode and allowed
to disperse. Anti-PSA antibodies were immobilized by
physical and chemical binding. Besides AuNPs, other
subtypes of gold nanomaterials were also reported to
improve the sensor performance: gold nanorods (AuNRs)
[53,87] and nanoporous gold (NPG), that can also be used
to efficiently immobilize the bioreceptor element. Wei
et al. [66] prepared a NPG film with uniform pore size
and large surface area by a dealloying method, which
allowed the adsorption of the antibody into the pores of
the film and provided a low detection limit.
On the other hand, carbon-based nanomaterials are
also used in transducer surface modifications because of
several reasons: (i) the increase of the surface area and
subsequent increase of sensitivity; (ii) immobilization of a
large amount of biomolecules, and (iii) their unique
characteristics and properties, especially their excellent
electrical conductivity [108]. Distinct dimensional carbon-
based nanomaterials can be used, such as carbon nano-
tubes (CNTs) that contemplate single-walled carbon
nanotubes (SWCNTs) [17] and multi-walled carbon nano-
tubes (MWCNTs) [51,86] or graphene (Gra) which
contemplates graphene (nano) sheets (GS) [59,65,67],
nitrogen-doped graphene sheets (N-GS) [20,22,35], gra-
phene oxide (GO) [33,58] and reduced graphene oxide
(rGO) [21,101]. Recent progress in the synthesis of
graphene-based hybrid nanomaterials have made them
even more appreciated, benefiting from the electrochem-
ical catalytic properties and the higher electron transfer
rate between the electrode and the detection molecules
[15,109]. For example, Zhang et al. [15] reported a
sandwich-type immunoassay using carbon nanosphere-
functionalized graphene hybrid nanosheets on a glassy
carbon electrode (GCE) as sensing platform. The use of
functionalized graphene nanosheets increases the surface
area for the immobilization of biomolecules.
Furthermore, the conjugation between gold- and
carbon-based nanomaterials and/or ionic liquids offer
multiple options in the sensor’s construction. Improved
performances were achieved using distinct combinations,
such as AuNC/nickel hexacyanoferrate NPs/AuNP-GS
[18], MWCNTs/AuNPs [24,60], AuNPs/Fc-rGO [34],
AuNPs-porous GO [41], MWCNTs/gold colloids [43],
Nafion/MWCNTs/AuNPs [61], AuNRs/CNTs [81], gold
nanowires (AuNW)/GS [84], chitosan (CS)-SWCNTs/
AuNPs [94], rGO/nafion/AuNPs [96], AuNPs/PDA/TH/
GO [97].
For example, Yang et al. [41] reported a sensing
platform composed of AuNPs functionalized porous
graphene (Au-PGO). In this sandwich-type electrochem-
ical immunosensor for the determination of CA 19-9, an
Au-PGO nanohybrid structure provided a large accessible
surface area for the immobilization of the antibodies,Ta
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which also facilitated electron transfer, leading to a
further enhancement of the sensor’s sensitivity. In addi-
tion, Li et al. [84] reported an immunosensor for the
detection of AFP using a hybrid nanostructure for
effective antibody immobilization. The sensing platform
was prepared by in situ solution-phase synthesis using
non-covalent ultrathin gold nanowires (AuNWs) function-
alized graphene sheets (GS). The water-soluble AuNWs/
GS hybrid allowed efficient electrochemical sensing and
combined the advantages of the carbon- and gold- based
nanomaterials. The developed sensor was successfully
applied to the analysis of serum samples from both
healthy individuals and cancer patients.
Besides gold and carbon, other nanomaterials have
also been used to easily conjugate nano- and biomaterials
and biomolecules in the construction of disposable and
sensitive immunosensors and immunoassays. Hong et al.
[38] developed an electrochemical immunosensor for the
detection of CA 15-3 using ferrocenecarboxylic acid (Fc-
COOH)-doped silica nanoparticles (SNPs) as an affinity
support on a AuE. The use of colloidal silica prevented
the leakage of Fc-COOH which was easily modified with
a trialkoxysilane. The NH2 groups on the nanoparticles’
surfaces allowed the covalent immobilization of CA 15-3
antibodies using glutaraldehyde as crosslinking agent. In
another work, Yang et al. [52] electrodeposited AuNPs
onto the surface of a Pd@flower-like SnO2 nanocomposite
for effective antibody immobilization, leading to an
enhancement of the sensitivity of the immunosensor. In
another approach, Li et al. [64] developed a label-free
immunosensor for PSA detection based on the binding of
the antibody to a thin film composed of graphene sheet
(GS) and cobalt hexacyanoferrate nanoparticles (CoNP)
on a GCE. The synergistic effect between the nano-
materials was investigated and showed that the electro-
activity of CoNP was greatly improved in the presence of
GS and that the formed composite film displayed high
electroactivity and good stability.
Based on the unique characteristics of an graphene/
SnO2/Au nanocomposite, an immunosensor for AFP
detection was developed through layer-by-layer self-
assembly on a GCE [83]. The good biocompatibility of the
nanocomposite provided suitable conditions for the inter-
action between antibody and antigen and the combination
of graphene, SnO2 and Au provided the efficient detection
of the biomarker.
Xu et al. [71] reported an immunosensor that could be
applied to the analysis of AFP in whole blood samples by
using heparin-polyglutamic-polypyrrole (Hep-PGA-PPy)
nanoparticles. The construction of the sensor was based
on the immobilization of anti-AFP antibodies on the Hep-
PGA-PPy nanoparticles that were then dropped on a
GCE surface (previously modified with APTES) and fixed
on the sensing surface through electrostatic bonding. The
Hep-PGA-PPy nanoparticles improved the anti-biofoul-
ing effect of the electrode by combining the distinct
characteristics of the nanoparticle components. The
developed immunosensor exhibited a low limit of detec-
tion (0.099 ng/mL).
Biomaterials have also been introduced in the surface
modification strategy and are often coated with nano-
materials to improve the performance of the biosensor
[54,62,91,99]. An interesting work developed by Gao
et al. [99] was based on polyamidoamine dendrimers
capped-carbon dots (PAMAM-CDs)/Au nanocrystal
nanocomposites as an immobilization matrix on a GCE
for sensitive immunosensing of AFP. The referred matrix
offered the possibility to combine distinct nanomaterials
to form nanocomposites, which exhibited excellent con-
ductivity, stability and biocompatibility of the electrode’s
surface.
6 Antibody Immobilization
For the development of immunosensors, as for the
majority of biosensors, the immobilization of the antibody
on the sensor‘s surface is crucial to achieve adequate
performance characteristics (e.g. high sensitivity and
precision, short response times, etc.) and long-term
stability. It is therefore important to minimize antibody
denaturation and conformational changes during or after
immobilization [110]. The orientation of the antibodies
and the low non-specific adsorption on the sensing surface
are critical factors for the effective detection of the
antigen. In general, the antibodies’ functional groups are
allowed to react and bind with the functional groups
available on the distinct (modified) sensing platforms.
Thus, for the development of electrochemical immunosen-
sors several antibody immobilization strategies have been
explored, including: non-covalent (adsorption and entrap-
ment), covalent and affinity approaches.
The adsorption strategy is the most easily performed
and consists of casting an antibody solution on the
electrode’s surface or dipping the electrode in an antibody
solution. Then, after an appropriate incubation time, the
electrode is washed to remove non-adsorbed antibodies.
The major drawbacks of this technique are the random
orientation of the antibodies, which exhibit lower antigen
binding capacities than properly orientated antibodies
[110], and the formation of weak bonds between the
antibody and the transducer, which can lead to the loss of
antibody during analysis and storage. In the adsorption
process, the interaction between the antibodies and the
electrode surface can be classified as electrostatic or
hydrophobic. In this strategy, distinct carbon- and gold-
based nanomaterials are typically used as platforms for
the efficient binding of antibodies. The interaction
between antibodies and gold nanomaterials (mainly
AuNPs) are usually achieved by chemisorption via thiol
derivatives, involving a chemical adsorption process
between the nanomaterial surface and the adsorbent
surface, which causes the bond to be created [14,25,27,48,
69,78,80,85,87]. As an example, Wang et al. [14] de-
scribed the immobilization of antibodies through adsorp-
tion onto AuNPs electrodeposited on a hydrogel film, that
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was used as an electrochemical immunosensing substrate
for the detection of NSE in serum samples.
Another type of non-covalent immobilization is
entrapment. In this process, the biological recognition
element can be immobilized within a suitable matrix.
Normally, the biocomponent is mixed with the support-
ing (nano) material and then deposited on the electrode
surface. Electropolymerization is also often used for
biomolecule entrapment. Moon et al. [55], suggested a
label-free immunosensor for PSA by incorporating the
anti-PSA antibody into polypyrrole. The electropolyme-
rization of polypyrrole on an Au nanowire array was the
key strategy in this study where anti-PSA antibodies
could simultaneously be immobilized on individual
polypyrrole nanowires, without additional modification
steps, resulting in enhanced molecular interactions. The
nanowires served as an efficient reservoir for the
incorporation of high concentrations of anti-PSA anti-
bodies. Indeed, the large surface area and well-defined
nanowire structure make them ideal for efficient anti-
body immobilization and thus, to enhance the loading
capacity. In addition, the preferential electrostatic
association between positive charges of the oxidized
polypyrrole chains and negative carboxyl groups on the
antibody allows strong immobilization while ensuring
antigenic epitope conservation.
Very stable linkage of the antibody to the sensor
surface can be achieved through covalent binding between
functional groups present on the (chemically modified)
transducer surface and the antibody. Nevertheless, care
must be taken not to bind functional groups essential for
antigen binding. Examples of compounds used for this
purpose are the well-known combination of 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide and N-hydroxysucci-
nimide (EDC/NHS). Glutaraldehyde (GA), 1-pyrenebuta-
noic acid succinimidyl ester (PBSE), phthaloyl chloride
and iminithiolane can also be used. Many immunosensors
were described in which carbodiimide chemistry was
employed for antibody immobilization [17,26,31,32,
35,51,57,58,65, 82,86,90,101]. In general, in this process
the primary amine groups of the antibody are covalently
bound to the carboxylic acid group present on the sensor
surface, through reactive succinimide esters by amine
coupling through EDC/NHS chemistry. On the other
hand, aldehyde modification is a suitable strategy to use
when the sensor’s surface is functionalized with materials
containing chemical groups such as amines or alcohols to
form imines. Basically, the modified sensing surface is
treated with glutaraldehyde (or other aldehydes) that is
allowed to react with the antibodies’ functional groups.
Like this, the binding between the surface and the
biological compound is accomplished through the cross-
linking agent [20–22,36,38,40, 46,50,59,68,79].
Antibodies can also be covalently immobilized onto
the working electrode through PBSE, based on an
amidation reaction between the available amine groups of
the antibody and the succinimidyl ester group of PBSE
[64,67]. Yang et al. [67] developed an immunosensor for
prostate cancer biomarker detection by immobilization of
the primary antibody onto the surfaces of GS through
PBSE which was adsorbed onto the nanomaterial through
p–p stacking.
In addition, self-assembly provides a convenient and
simple way of creating a highly ordered thin molecular
film with tailored chemical properties. In this process, the
thin molecular layer is formed by adsorption of molecules
from solution onto a solid surface. Subsequently, the
adsorbates spontaneously arrange themselves until a
completely ordered molecular monolayer is formed, which
is called the self-assembled monolayer (SAM) [111], and
onto which antibodies can be immobilized. Qu et al. [68]
used cysteamine to produce a SAM on the sensor
platform and covalently bound the capture antibody
through glutaraldehyde. Emami et al. [28] proposed the
construction of a label-free immunosensor composed of
distinct layers for HER2 detection. Firstly, AuNPs were
electrodeposited on a gold electrode surface, followed by
the immersion of the electrode in a 3-mercaptopropionic
acid (MPA) solution to form the SAM. Then, ECD/NHS
was added to activate the carboxyl groups of the MPA
layer. Subsequently, cysteamine was added and bound via
amide formation. Thereafter, pegylated magnetic iron
nanoparticles bound to the thiolated antibodies were
added to the previously formed layer-by-layer sensing
surface.
Affinity as an immobilization process consists of the
interaction between intermediate binding biomolecules
(e.g. Protein A, Protein G, biotin, avidin or streptavidin)
or carbohydrates (b-cyclodextrin) and a part of an anti-
body, known as the Fc region. These non-covalent
interactions are usually very strong and are adequate to
preferentially orient the antibodies and immobilize them
successfully on the electrode platform.
Li et al. [94] reported a multi-step sensor platform
approach by casting SWCNTs dispersed in chitosan
(CSSH-SWCNTs) on the electrode. This process allowed
the formation of a multitude of thiol groups (SH) onto
which AuNPs were immobilized. Subsequently the elec-
trode was incubated with protein A (PA) which provided
adequate orientation of antibodies on the electrode
surface. Park et al. [33] compared the biosensing perform-
ance of electroreduction-based electrochemical-enzymatic
redox-cycling schemes for the detection of cancer antigen
CA 15-3 by using avidin in the surface modification. In
this sensor, biotinylated anti-CA-15-3 IgG antibodies
were placed on avidin-modified ITO electrodes for
adequate orientation (Figure 1), and a detection limit of
0.100 U/mL was obtained.
7 Assay Formats (Immunochemical Interactions)
In EI, the most common immunochemical (antibody-
antigen) assay formats are: non-competitive (sandwich),
label-free and competitive assays, which are schematized
in Figure 2.
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In the non-competitive (sandwich) assay, a capture
antibody is immobilized on the electrode‘s surface which
is subsequently blocked using an inert protein (e.g. BSA
or casein) to avoid non-specific adsorption. The sensor is
then incubated with the sample, and the antigen (cancer
biomarker) is bound to the antibody‘s binding site. Then a
secondary antibody is added to complete the sandwich
format. In this type of assays the secondary antibody is
usually labelled to enable the detection of the antibody-
antigen interaction and/or to enhance the analytical signal
[27]. Enzymes such as alkaline phosphatase (AP), horse-
radish peroxidase (HRP) are classic examples of such
labels. When enzymatic labels are used, the enzymatic
substrate is placed on the sensor’s surface after the
incubation with the secondary antibody and one of the
enzymatic reaction products can be monitored. In this
case, the electrochemical signal is proportional to the
concentration of the electroactive product which in turn is
proportional to the amount of enzymatic label and
subsequently to the concentration of the antigen in the
sample. The use of enzyme labels provides significant
signal amplification, resulting in extremely low detection
limits [112]. In EI for the analysis of cancer biomarkers,
the most frequently used enzymes are AP and HRP.
Examples of immunosensors in which the AP label was
used are: Marques et al. [27] for the detection of HER2
and Escamilla-Gomez et al. [69] for the detection of PSA.
In these works, the antibody-antigen interaction was
measured by using a combination of 3-indoxyl phosphate
(3-IP), an enzymatic substrate of AP, and silver ions
(Figure 3), leading to the formation of metallic silver
which was detected by LSV. The use of silver ions
increases the electrochemical signal when compared to
the use of 3-IP alone, allowing detection limits below the
cut-off values for the mentioned biomarkers (4.4 ng/mL
for HER2 and 1.0 ng/mL for PSA).
In another approach, the use of liposomes, as carriers
of the marker molecules, can also amplify the signal and
improve the sensitivity of the immunosensor. A similar
sandwich assay developed by Escamilla-Gomez et al. [69]
for PSA detection was performed by Qu et al. [68].
However, in the latter study, AP was encapsulated in
liposomes. After the immunological interactions, the
bound liposomes were lysed with Triton X-100 to release
the encapsulated AP, which converted ascorbic acid 2-
phosphate (AA-p) into ascorbic acid and, in the presence
of silver ions, led to deposition of the metallic silver.
Besides the use of AP, HRP is used in a wide range of
sensor approaches. In the sensor developed by Mucelli
et al. [30], secondary antibodies labelled with HRP and
methylene blue (MB) were used to detect the interaction
between the protein and the antibody. MB is extensively
employed as mediator or electrochemically active agent in
cancer biosensors. Here, the electrochemical signal is
generated by MB (added as soluble mediator) which
shuttles electrons from the electrode to HRP during the
enzymatic reaction with its substrate, H2O2. In addition,
Biscay et al. [49], Guo et al. [81] and Zhong et al. [90]
Fig. 1. Schematic Representation of an Electrochemical Immuno-
sensor based on GO and Avidin modified sensing platform [33].
Re-drawn using Inkscape software.
Fig. 2. Types of immunoassays (I – immobilized antibodies react
with free antigens in competition with labelled antigens, II –
immobilized antigens react with free and labelled antibodies.
Fig. 3. Schematic representation of a sandwich immunosensor for
breast cancer protein biomarker detection [27]. Re-drawn using
Inkscape software.
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used similar methodologies based on HRP as label and
3,3’,5,5’ tetramethylbenzidine (TMB) as co-substrate. The
authors combined TMB and H2O2 to apply a less positive
potential and thus avoid some interferences.
Enzymes can also be combined with metallic (nano)
materials and/or with redox mediators to obtain more
efficient electrochemical signal amplifications. In the work
developed by Li et al. [94] a sandwich-type electrochem-
ical immunoassay was constructed based on an efficient
signal amplification strategy using hollow AuNPs, HRP
NP bioconjugates and TH. Here, TH was used as
mediator between HRP enzyme and the electrode surface,
and then HRP could synergistically catalyse H2O2. TH is
highly redox active and improves the intensity of the
signal (Figure 4).
However, the drawbacks of loaded enzymes limit their
use as labels in electrochemical immunosensors because
of: (i) easy inactivation; (ii) costly preparation; (iii)
laborious purification processes. Therefore, nanomaterials
with electrocatalytic properties for the electrochemical
detection of H2O2 are frequently employed to: (i) enhance
the sensitivity achieved in the analysis, (ii) reduce the
detection potential to minimize the interference of other
species present in the sample. A disadvantage of H2O2
detection is the high detection potential, which can also
lead to the oxidation of other substances present in the
sample.
Jiang et al. [80] developed an amplification option for
a sandwich-type immunosensor based on biotin-function-
alized amination of a magnetic nanoparticle composite
(B-APTES@Fe3O4) as label for detection of AFP. The
strategy was successfully implemented using a biotin-
streptavidin-biotin (B-SA-B) network. Here, further sig-
nal amplification could be achieved as SA and
BAPTES@Fe3O4 are added layer by layer on the
electrode. In addition, B-APTES@Fe3O4 was used as label
of the secondary antibody, which catalysed the electro-
chemical reaction of H2O2.
In the immunosensor for PSA detection developed by
Chu et al. [48], Pd@Cu2O NPs were used as label and
presented the excellent characteristics of palladium- (Pd
NPs) and cuprous oxide nanoparticles (Cu2O NPs).
An enzyme-free immunosensor for PSA detection was
constructed by Sun et al. [53], using porous zinc oxide
spheres-silver nanoparticles (ZnO2AgNPs) nanocompo-
sites as signal labels. The large surface area of ZnO2
provided sites for the inclusion of AgNPs which improved
their catalytic capacity toward H2O2 reduction. This
allowed the construction of enzyme-free electrochemical
sensors which are cheaper and simpler than enzyme-
labelled immunosensors.
Moreover, metal ions and quantum dots (QDs) seem
to be promising candidates as labels. Commercially
available QDs are normally preferred because their
preparation is complicated and tedious. However, the
drawbacks of using QDs include the rather harsh con-
ditions needed to dissolve QDs and the need for a highly
sensitive stripping technique to obtain the signal [32].
Distinct sensing strategies for metal ions/QD-based bio-
sensors can be performed by using several ions (e.g. Cd2+,
Pb2+, Cu2+, Zn2+) for direct labelling, avoiding the above-
mentioned problems. Zhao et al. developed an immuno-
sensor for detection of the breast cancer biomarker CA
15-3 where Cd2+-functionalized nanoporous TiO2
(TiO2Cd2+) was used as label for the detection of the
signal [32]. Nanoporous TiO2 spheres were used because
of its highly specific surface area (functionalized with
abundant NH2 groups) which are favourable for the
adsorption of high amount of Cd2+ which was subse-
quently detected by SWV, allowing to obtain a detection
limit of 0.008 U/mL.
In the label-free approach the antibody-antigen inter-
action is detected directly without the need of a secondary
antibody. This simplifies the immunoassay, allowing faster
and cheaper analysis [113]. In these assays, like in the
sandwich technique, an antibody is immobilized on the
transducer’s surface and the immunocomplex is formed
after incubation with a sample. Then a redox probe is
placed on the sensor and the analytical signal is recorded.
The amplitude of this signal decreases with increasing
antigen concentration because of the electron transfer
hindrance caused by the formed immunocomplex. The
most commonly employed redox probes in the label-free
approach for cancer immunosensors are: [Fe(CN)6]
3/4
[18,24,25,28,35, 46, 50,55,57,61,66,87,95,99], Prussian
blue (PB) [19,39], Ferrocene (Fc) [34,54], Ferrocenecar-
boxylic acid (Fc-COOH) [38], Methylene Blue (MB) [62],
Cobalt hexacyanoferrate NPs [64], thionine (TH) [79,97],
[Ru(NH3)6]
3+ [83], H2O2 [89,91,92], Azure I [98]. As an
example, the [Fe(CN)6]
3/4 redox probe was used by Deng
et al. [46] in a label-free immunoassay for trace species
analysis, based on the “gate-effect” of a b-cyclodextrin (b-
CD) layer. In this work, the detection of PSA was carried
out using a b-CD assembled layer, which created gates for
Fig. 4. Electrochemical signal amplification strategy [94]. Re-
drawn using Inkscape software.
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the electron transfer of the probe. The monoclonal anti-
body labelled b-CD and the interspaces between b-CD
molecules in the layer were formed on the electrode,
which act as a channel for the electron transfer from the
probe (Figure 5). By virtue of the “gate-effect”, signal
amplification and enhancement of the signal-to-noise ratio
was achieved.
Moreover, Mao et al. [62] used Methylene Blue (MB)
as the redox probe in a label-free EI based on a
nanocomposite film composed of graphene sheets-
methylene blue-chitosan (GS-MB-CS). The film was used
as electrode material to immobilize the antibody because
of the high nanocomposite film binding affinity to the
electrode. Another example of a redox probe is
[Ru(NH3)6]
3+ that was used in a label-free immunosensor
for the detection of AFP by monitoring the peak current
change [83]. In this work, a graphene/SnO2/Au nano-
composite sensor platform was used to immobilize the
capture antibody. A decrease in the peak current intensity
of [Ru(NH3)6]
3+ was related to the interaction between
antibody and antigen.
Another assay type with a reduced number of
applications in electrochemical immunosensing of cancer
biomarkers is the competitive immunoassay. In this assay
(i) immobilized antibodies react with free antigens in
competition with labelled antigens or (ii) immobilized
antigens react with free and labelled antibodies [114]. The
labels employed are identical to the ones used in non-
competitive assays. Yu et al. [17] developed a competitive
electrochemical immunosensor for the detection of NSE
in serum. In the sensing phase construction, a drop of
SWCNTs was cast onto a GCE electrode and EDC/NHS
was added to activate the carboxyl groups, allowing
efficient NSE binding. In this competitive format, the high
loading of NSE on SWCNTs greatly extended the limit of
the detectable range. For the competitive immunoreac-
tion, the sensor was incubated with the sample (containing
‘free’ NSE) and anti-NSE antibodies. For the signal
readout, AP-anti-IgG/AuNP was used, that exhibited high
catalytic activity toward the hydrolysis of a-NP in DEA
buffer (Figure 6).
8 Magnetic Immunoassays
In addition to the previously mentioned sensor surface
modification based on nanomaterials and biomaterials,
magnetic beads (MBs) are powerful tools for bioassays
because of, for example, the increase of the surface area
and the improvement of the sensitivity of the detection
method [115]. Their use, combined with modified elec-
trode surfaces improves biomolecule interactions and
reduces or/and minimizes the matrix effect of the sample
by efficient washing steps [116]. MBs can be manipulated
with an external magnet that enables biological reaction
events to be performed away from the electrode and can
be retained on a sensor surface by an external magnetic
field through, for example, the placement of small
magnets below the surface of the working electrode
(normally with the corresponding size of the WE). There-
fore, the recognition element is not in direct contact with
the electrode surface, which constitutes the major draw-
back related to the use of MBs [117]. MBs can be
functionalized with distinct recognition elements generally
through (i) affinity agents (e. g. Protein A, streptavidin)
and (ii) covalent binding (e.g. EDC/NHS, GA, SAMs)
(Figure 7).
Ilkhani et al. [23] reported three simple magnetic
bead-based approaches, combined with screen-printed
arrays, for the analysis of HER2. The bioassays were
based on a sandwich format in which affibody (Af) or
antibody molecules were immobilized on streptavidin- or
protein A-modified MBs (Strept-MBs or Prot A-MBs).
Both types of MBs could be used for immuno-precipita-
tion purposes.
Al-Khafaji et al. [29] reported a magnetic immuno-
assay for HER2 detection by using protein A-modified
magnetic beads. The proposed assay was based on a
sandwich format in which antibody-functionalised mag-
netic beads were used to capture the protein biomarker.
Then, anti-HER2 antibodies labelled with AP were added
to trace the affinity reaction, using 1-naphthyl-phosphate
as enzymatic substrate and DPV for signal detection.
Fig. 5. Example of a label free assay, using [Fe(CN)6]
3/4 as redox
probe [46]. Re-drawn using Inkscape software.
Fig. 6. Schematic representation of Competitive electrochemical
immunosensor for NSE detection [17]. Re-drawn using Inkscape
software.
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Biscay et al. [49] investigated a screening device using
magnetic beads as solid phase to develop an immunoassay
for the detection of total PSA (tPSA) in serum. Here, the
tPSA detection was performed by using superparamag-
netic beads (1 mm) modified with streptavidin and an 8-
channel screen printed electrode array. In this assay, a
mixture of biotinylated antibodies and HRP-labelled anti-
bodies were added to a previously prepared solution
containing Strep-MBs and PSA, forming a sandwich
complex. Then, TMB was added, which was subsequently
oxidized in the reaction cascade and detected by chro-
noamperometry.
9 Simultaneous/Multiplex Detection
Screening and early diagnosis of cancer contributes to
prognosis judgement and appropriate treatment of the
patient. In clinical practice, the determination of a single
specific biomarker is facing a great challenge and has
limitations because of the poor specificity and sensitivity
between the tumour biomarker and the cancer type. Thus,
simultaneous detection of multiple biomarkers is of
utmost importance and may confer high diagnostic
specificity of the disease. To address this, the design of
(bio) sensors for the simultaneous detection of multiple
tumour biomarkers has demonstrated significant improve-
ments.
Multiplexed electrochemical immunoassays and/or im-
munosensors are feasible options to detect, identify and
quantify two or more biomarkers in the same sample. A
major issue in the development of these assays is related
to the distinction between the signals of the multiple
antigenantibody interactions. One option is to use multi-
working electrode sensors in which each WE is modified
with a specific capture antibody. Another option is the use
of antibodies with distinct labels (multi-labelling). In this
last approach, the electrochemical detection based can be
performed on single WE sensors.
Escamilla-Gomez et al. [69] reported the use of SPCEs
that contain two carbon working electrodes for the
simultaneous determination of prostate specific antigen
(free PSA and total PSA). In this sensor, 8A6 anti-PSA
and 5G6 anti-PSA antibodies were separately immobi-
lized, through adsorption, on each of the WEs. Then,
biotinylated antibodies and an S-AP conjugate were
added, and the detection was accomplished using a
substrate solution containing 3-IP and silver ions. The
analytical signal was obtained by LSV and the results
showed the feasibility of the simultaneous detection of
fPSA and tPSA in human prostate tumour cells.
A similar approach with multi WE sensors was
reported by Marques et al. [118]. In their strategy, a
multiplexed electrochemical immunosensor for the simul-
taneous detection of two breast cancer biomarkers (CA
15-3 and HER2-ECD) was developed based on a custom-
ized dual screen-printed carbon electrode (bi-SPCE)
nanostructured with in situ generated gold nanoparticles.
The application of this bi-immunosensor was based on the
antigen-antibody interactions, in which specific capture
antibodies for these biomarkers were immobilized by
adsorption on each nanostructured working electrode, and
the electrochemical signals were detected by LSV analysis
of enzymatically (AP) generated metallic silver (Figure 8).
The immunosensor’s limits of detection were 5.0 U/mL
for CA 15-3 and 2.9 ng/mL for HER2-ECD.
10 Cytosensors
One of the major current challenges in cancer diagnostics
and follow-up is the analysis of circulating tumour cells
(CTCs). CTCs are cells that are shed from a primary
tumour and circulate in the body. They contain a large
amount of information on the tumour phenotype [119].
Due to the important information that can be obtained
from CTCs, several detection methodologies have been
developed that contribute to a more efficient diagnosis.
Therefore, cytosensors have emerged as an innovating
area related to electrochemical (bio) sensors. Cytosensors
Fig. 7. Strategies on immobilization of recognition element onto
the surface of magnetic particles.
Fig. 8. Schematic representation of multiplexed detection of
cancer biomarkers [118]. Re-drawn using Inkscape software.
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are a class of biosensors that can detect specific cells
through their recognition by, for example, antibodies,
aptamers, DNA, that are immobilized on a transducer
surface. Although the analysis of CTCs is important in
diagnosis, no analytical devices are currently available
that allow their effective detection with low costs, small
sample volumes and in situ detection.
CTCs originating from epithelial tumours express the
epithelial cell adhesion molecule EpCAM [119–121].
Recently, cytosensors for CTCs detection using EpCAM
have been described [122,123]. Shen et al. [122] developed
a reusable cytocensor with self-assembled monolayers
deposited onto an AuE to directionally insert the capture
probe (EpCAM aptamer) which specifically binds to
EpCAM over-expressed on the membrane of breast
cancer MCF-7 cells. The electrochemical response of this
label-free cytosensor towards MCF7 cells was recorded by
EIS using the redox probe [Fe(CN)6]
3/4. Maltez-da Costa
et al. [123] developed a strategy for a simple monitoring
and rapid electrochemical biosensing for CTCs quantifica-
tion using specific antibodies labelled with magnetic beads
(MBs). Human colon adenocarcinoma cell line (Caco2)
was chosen as a model CTC because, similarly to other
adenocarcinomas, Caco2 have a strong expression of
EpCAM. In this cytosensor, the authors combined anti-
EpCAM antibody-functionalized MBs with antibody-
modified AuNPs in liquid suspensions. The detection of
the labelled Caco2 cells was performed by chronoamper-
ometry through the hydrogen evolution reaction, using
1 M HCl, that was electrocatalyzed by the AuNP labels. In
another work, HER2-overexpressing cells could be de-
tected using a hydrazine-AuNP-aptamer bioconjugate
[124]. The developed sensor could differentiate between
HER2-positive and HER2-negative breast cancer cells
and could be applied to diagnosis through either HER2
protein or SK-BR-3 breast cancer cell in human serum
samples. In the detection process the sensor was placed in
a silver nitrate solution where silver ions were selectively
reduced to metallic silver by hydrazine which was then
oxidized using square wave stripping voltammetry
(SWSV). Lu et al. [125] developed an electrochemical
cytosensor for lung cancer cell detection that could
sensitively differentiate A549 cells from normal ones (AT
II cells) using an epidermal growth factor (EGFR) anti-
body to recognize EGFR receptors that are over-ex-
pressed on the cancer cells. To avoid the drawbacks
related to the use of extra immobilization agents and
enzymes, AuNPs decorated m-aminophenol based resin
microspheres were used to act as suitable immobilization
carriers and to facilitate electron transfer. The detection
strategy used in this approach was based on the electron
transfer blockage of the immunocaptured A549 cells.
11 Conclusions
The continuous progress and the evolution of analytical
methodologies allow an increasingly effective diagnosis
and follow-up of cancer. In this review, a short summary
of recently developed voltammetric and amperometric
immunoassays and cytosensors for the analysis of the six
most commonly diagnosed cancer biomarkers is pre-
sented. A survey of the published studies shows that the
attention in this research area is now mainly focussed on
the increase of the sensitivity through different types of
electrode surface modifications (carbon- and gold- based
nanomaterials, nanoparticles, nanocomposites, SAMs and/
or biomaterials) and detection labels of (secondary) anti-
bodies. Magnetic immunoassays also constitute an ad-
equate strategy because of the inherent advantages of
using magnetic particles, since they enhance the inter-
actions of the biomolecules and minimize the effect of the
sample matrix. Moreover, the development of sensors that
provide simultaneous or multiplexed detection contributes
to a better prognosis and more efficient screening. The
development of cytosensors is currently a challenge to
improve cancer detection.
The low limits of detection attained with the devel-
oped sensors allows the detection of cancers in an early
stage, which could prevent the deaths of millions of
people and reduce the suffering of patients and their
families and the cost to society. Furthermore, their high
sensitivity enables the detection of only slight changes in
the biomarker concentration. This could be an excellent
additional tool for monitoring cancer patients during
treatment and follow-up.
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